Bacil Pharma Board of Directors

Get the latest insights into the leadership at Bacil Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Dinesh Chander NotiyalNon Executive Independent Director
Avani Savjibhai GodhaniyaNon Executive Independent Director
Chaitali Kalpataru ShahExecutive Director & Chief Financial Officer
Vivek Mukesh YadavNon Executive Independent Director
Dikshant Singh PanwarCompany Secretary

Bacil Pharma Share price

BACPHAR

59

0.05 (0.08%)
Last updated on 22 Apr, 2026 | 11:47 IST
Today's High

61.80

Today's Low

56.06

52 Week Low

26.69

52 Week High

61.80

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Bacil Pharma FAQs

The board at Bacil Pharma consists of experienced professionals, including Dinesh Chander Notiyal, Avani Savjibhai Godhaniya, and others, overseeing the company’s strategic and corporate governance.

Directors at Bacil Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Dinesh Chander Notiyal is the current chairman at Bacil Pharma.

Executive directors at Bacil Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Bacil Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Bacil Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost